Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamara P Miller

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Current Hematologic Malignancy Reports|March 31, 2021
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care DeliveryTamara P Miller, Richard Aplenc
Hematology. American Society of Hematology. Education Program|December 9, 2023
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollmentSanyukta K Janardan, Tamara P Miller
Hematology. American Society of Hematology. Education Program|December 4, 2020
Improving symptom control and reducing toxicities for pediatric patients with hematological malignanciesLillian Sung, Tamara P Miller, Robert Phillips
Development (Cambridge, England)|July 16, 2010
Sec5, a member of the exocyst complex, mediates Drosophila embryo cellularizationMala Murthy, Rita O Teodoro, Tamara P Miller, et al.
Pediatric Blood & Cancer|September 6, 2019
Feasibility and acceptability of an animatronic duck intervention for promoting adaptation to the in-patient setting among pediatric patients receiving treatment for cancerTamara P Miller, James L Klosky, Fernanda Zamora, et al.
Leukemia & Lymphoma|December 1, 2020
Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemiaZachary E West, Sharon M Castellino, Caitlin Monroe, et al.
Journal of Pediatric Hematology/Oncology|June 23, 2026
Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia TherapyHolly J Edington, Nicholas P DeGroote, Jason Stevenson, et al.
Pediatric Blood & Cancer|July 13, 2023
High burden of clinically significant adverse events associated with contemporary therapy for pediatric T-cell acute lymphoblastic leukemia/lymphomaRyan J Summers, Vanessa M Monroig, Nicholas P DeGroote, et al.
Pediatric Blood & Cancer|September 4, 2020
Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropeniaKaitlin Shinn, Martha Wetzel, Nicholas P DeGroote, et al.
Pediatric Blood & Cancer|December 25, 2023
Missing the mark? Exploratory analysis of the 10-year-old cutoff as an independent marker of high-risk disease in pediatric B-ALLPaul E George, Nicholas P DeGroote, Michaela Henderson, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Current Hematologic Malignancy Reports|March 31, 2021
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care DeliveryTamara P Miller, Richard Aplenc
Hematology. American Society of Hematology. Education Program|December 9, 2023
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollmentSanyukta K Janardan, Tamara P Miller
Hematology. American Society of Hematology. Education Program|December 4, 2020
Improving symptom control and reducing toxicities for pediatric patients with hematological malignanciesLillian Sung, Tamara P Miller, Robert Phillips
Development (Cambridge, England)|July 16, 2010
Sec5, a member of the exocyst complex, mediates Drosophila embryo cellularizationMala Murthy, Rita O Teodoro, Tamara P Miller, et al.
Pediatric Blood & Cancer|September 6, 2019
Feasibility and acceptability of an animatronic duck intervention for promoting adaptation to the in-patient setting among pediatric patients receiving treatment for cancerTamara P Miller, James L Klosky, Fernanda Zamora, et al.
Leukemia & Lymphoma|December 1, 2020
Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemiaZachary E West, Sharon M Castellino, Caitlin Monroe, et al.
Journal of Pediatric Hematology/Oncology|June 23, 2026
Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia TherapyHolly J Edington, Nicholas P DeGroote, Jason Stevenson, et al.
Pediatric Blood & Cancer|July 13, 2023
High burden of clinically significant adverse events associated with contemporary therapy for pediatric T-cell acute lymphoblastic leukemia/lymphomaRyan J Summers, Vanessa M Monroig, Nicholas P DeGroote, et al.
Pediatric Blood & Cancer|September 4, 2020
Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropeniaKaitlin Shinn, Martha Wetzel, Nicholas P DeGroote, et al.
Pediatric Blood & Cancer|December 25, 2023
Missing the mark? Exploratory analysis of the 10-year-old cutoff as an independent marker of high-risk disease in pediatric B-ALLPaul E George, Nicholas P DeGroote, Michaela Henderson, et al.
Pageof 7